Quince Therapeutics (QNCX) Non-Current Assets (2018 - 2026)

Quince Therapeutics has reported Non-Current Assets for 9 years, with the latest figure at -$119.2 million in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 219.32% year-over-year to -$119.2 million in Q2 2026; TTM through Jun 2026 was $33.1 million, a 81.72% decrease from a year earlier, with the FY2025 full-year figure at $70.6 million, changed 0.26% from the prior year.
• Non-Current Assets was -$119.2 million for Q2 2026 at Quince Therapeutics, down from $1.0 million in the prior quarter.
• The five-year high for Non-Current Assets was $90.5 million in Q4 2023, with the low at -$119.2 million in Q2 2026.
• Average Non-Current Assets over 5 years is $29.2 million, with a median of $19.1 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2026: Non-Current Assets surged 35017.84% in 2024, then sank 219.32% in 2026.
• Over 5 years, Non-Current Assets stood at $10.2 million in 2022, then soared by 790.18% to $90.5 million in 2023, then declined by 22.13% to $70.4 million in 2024, then increased by 0.26% to $70.6 million in 2025, then tumbled by 268.84% to -$119.2 million in 2026.
• The last three Non-Current Assets figures came in at -$119.2 million (Q2 2026), $1.0 million (Q1 2026), and $70.6 million (Q4 2025), per Business Quant data.